

RECEIVED

JAN 12 2004

TECH CENTER 1600/2900

The "Received" stamp of the Patent Office imprinted hereon acknowledges the filing of:

Applicant: Elizabeth M. Denholm, Elizabeth Cauchon and  
Serial & Docket No. Paul J. Silver IT 105

Filed: December 1, 2000

Papers Submitted: Express Mail # EL 381 201 122 US

New Patent Application entitled "ATTENUATION OF FIBROBLAST PROLIFERATION" (including 1 page Abstract, 21 pages Specification, 3 pages Claims, 5 sheets Drawings, executed Declaration); Utility Patent Transmittal; Fee Transmittal (in duplicate); Express Mail Transmittal Letter with Certificate of Mailing under 37 CFR 1.10 (in duplicate); Check for \$355.00.

Date: December 1, 2000

By: Patrea L. Pabst, Reg. No. 31,284

21024/14

DOCKETED FOR \_\_\_\_\_  
BY JCS  
DATE 12-8-00



RECEIVED

JAN 12 2004


TECH CENTER 1600/2900

EXPRESS MAIL TRACKING NO.: EL 381 201 122 US

DOCKET NO.: IT 105 - 21024/14

RESPONSIBLE ATTORNEY: Patrea L. Pabst

RESPONSIBLE SECRETARY: Jean Hicks



### INSTRUCTIONS FOR FILING OF A DOCUMENT BY EXPRESS MAIL

This document is being filed in the U.S. Patent and Trademark Office pursuant to 37 C.F.R. §1.10. This requires the following:

(1) The document must be delivered to the Post Office on the same day as the certificate of mailing is executed; this will be the same day it is delivered to the mail room at AG&G and the same day the mail room hands the document to the courier who picks up the mail.

(2) The express mail label must be completed by a living human being at the Post Office **AT THE TIME OF DELIVERY TO THE POST OFFICE; NOT LATER!** The following information **MUST** be completed on the form which is returned by the Post Office to AG&G:

- (a) PO ZIP
- (b) Date in
- (c) Time in

Typically, the Post Office will fill in additional information, but this is not critical.

### ACKNOWLEDGEMENT BY MAIL ROOM COURIER

I, TAMMY FOWLER of Courier Express  
[PRINT NAME] [COMPANY NAME]

on 12-1-00 have read and understand these instructions regarding delivery of this  
[DATE]

package to the U.S. Post Office.

DEC 04 2000

DEC 21 2000

Tammy Fowler  
[SIGNATURE]

IF FOR ANY REASON YOU ENCOUNTER A PROBLEM WITH THE DELIVERY OF THIS PACKAGE PURSUANT TO THE INSTRUCTIONS SET FORTH ABOVE, PLEASE CONTACT Patrea Pabst AT 404-873-8794 AND DUANE ROWAN AT (404) 870-5714 (OFFICE) or (404) 318-1166 (BEEPER).



**RECEIVED**

**JAN 12 2004**

**TECH CENTER 1600/2900**

**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Elizabeth M. Denholm, Elizabeth Cauchon and Paul J. Silver

Serial No.: Express Mail Label No.: EL 381 201 122 US

Filed: December 1, 2000 Date of Deposit December 1, 2000

For: ATTENUATION OF FIBROBLAST PROLIFERATION

Assistant Commissioner  
for Patents  
Washington, D.C. 20231

**EXPRESS MAIL TRANSMITTAL LETTER  
FOR PATENT APPLICATION AND CERTIFICATE OF MAILING**

Sir:

Pursuant to 35 U.S.C. § 21(a) as amended by Public Law 97-247 and 37 C.F.R. § 1.10, Elizabeth Denholm, Elizabeth Cauchon and Paul J. Siler enclose for filing the attached patent application entitled "ATTENUATION OF FIBROBLAST PROLIFERATION", which claims priority to U.S.S.N. 60/168,518 filed December 2, 1999. The application includes 1 page of Abstract, 21 pages of specification, 3 pages of claims, 5 sheets of informal drawings, and an executed Declaration. An Assignment to IBEX Technologies will be mailed shortly. A check in the amount of \$355.00 to cover the filing fee is enclosed.

This application is entitled to small entity status under 37 C.F.R. § 1.27.

This application is being filed on December 1, 2000 by mailing the application to the Assistant Commissioner for Patents, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10. The Express

"ATTENUATION OF FIBROBLAST PROLIFERATION"  
Filed December 1, 2000  
Express Mail Transmittal Letter for  
Patent Application and Certificate of Mailing  
Express Mail Label No. EL 381 201 122 US


Mail label number appears in the heading of this paper which is attached to the application papers pursuant to 37 C.F.R. § 1.10(b).

The Commissioner is hereby authorized to charge any fees that may be required, or credit any overpayment to Deposit Order Account No. 01-2507. To facilitate this process, applicants have enclosed a duplicate of this letter.

All correspondence concerning this application should be mailed to:


Patrea L. Pabst, Esq.  
ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3450

Respectfully submitted,

  
Patrea L. Pabst  
Reg. No. 31,284

Date: December 1, 2000

ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8794  
(404) 873-8795 Telefax



JAN 12 2004

TECH CENTER 1600/2900

PTO/SB/05 (08-00)

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	IT 105
First Inventor	Elizabeth M. Denholm
Title	ATTENUATION OF FIBROBLAST PROLIFERATION
Express Mail Label No.	EL 381 201 122 US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.  
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 25 ]  
(preferred arrangement set forth below)
  - Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [ Total Sheets 5 ]
5. Oath or Declaration [ Total Pages 3 ]
  - a. ☒ Newly executed (original or copy)  
Copy from a prior application (37 CFR 1.63 (d))
  - b. ☐ (for continuation/divisional with Box 17 completed)
    - i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s)  
named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

**ADDRESS TO:**Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☐ Computer Readable Form (CRF)
  - b. Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☐ paper
  - c. ☐ Statements verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Other: .....

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No.: \_\_\_\_\_ / \_\_\_\_\_

Prior application information:

Examiner: \_\_\_\_\_

Group / Art Unit: \_\_\_\_\_

**For CONTINUATION OR DIVISIONAL APPS only:** The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.**18. CORRESPONDENCE ADDRESS**☐ Customer Number or Bar Code Labelor ☐ Correspondence address below

Name	Patrea L. Pabst Amall Golden & Gregory, LLP				
Address	2800 One Atlantic Center 1201 West Peachtree Street				
City	Atlanta	State	GA	Zip Code	30309-3450
Country	United States	Telephone	(404) 873-8794	Fax	(404)873-8795

Name (Print/Type)

Patrea L. Pabst

Registration No. (Attorney/Agent)

31,284

Signature

Date December 1, 2000


Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**RECEIVED**

Page 1 of 4

JAN 12 2004

TECH CENTER 1600/2900



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/727,873	12/01/2000	1651	355	IT 105	5	19	2

CONFIRMATION NO. 7540

**FILING RECEIPT**

\*OC000000005691133\*

Patrea L. Pabst  
Arnall Golden & Gregory, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, GA 30309-3450

Date Mailed: 02/13/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**Elizabeth M. Denholm, Pointe Claire, CANADA;  
Elizabeth Cauchon, Ile Perrot, CANADA;  
Paul J. Silver, Spring City, PA;**Assignment For Published Patent Application**

IBEX Technologies,;

**Continuing Data as Claimed by Applicant**

THIS APPLN CLAIMS BENEFIT OF 60/168,518 12/02/1999

**Foreign Applications**

If Required, Foreign Filing License Granted 01/19/2001

Projected Publication Date: 06/06/2002

Non-Publication Request: No

Early Publication Request: No

**\*\* SMALL ENTITY \*\*****RECEIVED**

FEB 16 2001

PATENT DEPT.

**Title**

Attenuation of fibroblast proliferation

**Preliminary Class**

435

---

**Data entry by : AHMED, HEWAN**

**Team : OIPE**

**Date: 01/22/2001**

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).


**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:



Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231



"ATTENUATION OF FIBROBLAST PROLIFERATION"  
Filed December 1, 2000  
Express Mail Transmittal Letter for  
Patent Application and Certificate of Mailing  
Express Mail Label No. EL 381 201 122 US

RECEIVED


JAN 12 2004

TECH CENTER 1600/2900

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10**

I hereby certify that this Express Mail Transmittal Letter for Patent Application and any documents referred to as attached therein are being deposited with the United States Postal Service on this date, December 1, 2000, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, mailing label number EL 381 201 122 US, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: December 1, 2000

  
\_\_\_\_\_  
Jean Hicks